Management and Prevention of Neutropenia Supportive Care


Neulasta Significantly Reduces Febrile Neutropenia Among Colorectal Cancer Patients Receiving Chemotherapy Plus Avasatin (July 15, 2013)

Neulasta® (pegfilgrastim) significantly reduced the incidence of grade 3/4 febrile neutropenia among patients with locally advanced or metastatic colorectal cancer who received chemotherapy with FOLFOX... Continue Reading

Naproxen May Relieve Bone Pain Associated with Neulasta (August 2, 2012)

Twice-daily naproxen is effective in reducing the incidence and severity of bone pain associated with the use of Neulasta® (pegfilgrastim), according to the results of a study published in the Journal... Continue Reading

Celebrities Stand Up to Cancer (September 14, 2009)

Celebrities and Amgen are joining forces to Stand Up to Cancer™—in the form of a public service campaign designed to educate cancer patients and caregivers about managing the increased risk of infection... Continue Reading

Amgen Helps Reduce Out-of-pocket Costs for Neulasta® (July 2, 2009)

Amgen’s Neulasta FIRST STEP™ Program provides assistance to eligible, low-income, commercially-insured chemotherapy patients who need help with their co-insurance or co-payment requirement for Neulasta®... Continue Reading

Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma (September 9, 2008)

Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma Relative dose intensity (RDI) remains a key factor in the outcomes of patients with non-Hodgkins lymphoma (NHL). These results have... Continue Reading

Neulasta® Deemed Cost-effective for Prevention of Febrile Neutropenia in Breast Cancer Patients (August 15, 2008)

The prophylactic use of Neulasta® (pegfilgrastim) is cost-effective for the prevention of febrile neutropenia in patients undergoing treatment for breast cancer. The details of this study appeared in... Continue Reading

Early Use of Neulasta® Superior to Later Use In Elderly Patients Undergoing Chemotherapy (August 8, 2008)

The use of Neulasta® (pegfilgrastim) after the first cycle of chemotherapy among elderly patients undergoing chemotherapy decreases febrile neutropenia and associated effects compared with its use later... Continue Reading

Prophylactic Neulasta® Reduces Febrile Neutropenia and Early Deaths Among Patients Receiving Chemotherapy (July 31, 2008)

Prophylactic use of Neulasta® (pegfilgrastim) among cancer patients receiving chemotherapy reduces the risk of developing febrile neutropenia and early death. These results were recently published in... Continue Reading

Neulasta® on First Day of Chemotherapy May Be More Convenient for Gynecologic Cancers (March 17, 2008)

The administration of the blood cell growth factor Neulasta® (pegfilgrastim) on the first day of chemotherapy among women with gynecologic cancers may be as effective as and more convenient than second-day... Continue Reading

Myelosuppression: A Report from the 2007 International MASCC/ISOO Symposium (November 5, 2007)

Myelosuppression: A Report from the 2007 International MASCC/ISOO Symposium Introduction At the 2007, 20th Anniversary International MASCC/ISOO Symposium, neutropenia, thrombocytopenia, and anemia remained... Continue Reading

Myelosuppression: A Report from the 2007 ONS Annual Congress (October 15, 2007)

Myelosuppression: A Report from the 2007 ONS Annual Congress Introduction Myelosuppression was an important topic at the 2007 Oncology Nursing Society Congress. Two satellite symposia, two instructional... Continue Reading

Strategies for Preventing Infection in Cancer Patients with Neutropenia: A Report from the 2007 ONS Annual Congress (October 15, 2007)

Strategies for Preventing Infection in Cancer Patients with Neutropenia: A Report from the 2007 ONS Annual Congress Introduction Concern about the effectiveness of strategies routinely recommended for... Continue Reading

Updates on the Management of Hematopoietic Supportive Care – ASCO 2007 (October 12, 2007)

Updates on the Management of Hematopoietic Supportive Care – ASCO 2007 Introduction Chemotherapy induced alterations on bone marrow function, including myelosuppression, anemia, and thrombocytopenia,... Continue Reading

Neulasta® Reduces Risk of Neutropenia in Colorectal Cancer Patients (August 10, 2007)

According to the results of a study presented at the 9th World Congress on Gastrointestinal Cancer, Neulasta® (pegfilgrastim) reduces the risk of severe neutropenia (low white blood cell count) in colorectal... Continue Reading

Preventive Treatment Reduces Risk of Febrile Neutropenia and Early Death (August 3, 2007)

According to the results of a study published in the Journal of Clinical Oncology, preventive treatment with a granulocyte colony stimulating factor (drugs that boost white blood cell levels) reduces the... Continue Reading

Noxavil® May be Superior for Prevention of Fungal Infections in Cancer Patients (January 26, 2007)

Noxavil® May be Superior for Prevention of Fungal Infections in Cancer Patients According to two articles recently published in the New England Journal of Medicine, the anti-fungal agent Novaxil® (posaconazole)... Continue Reading

Early Use of Neulasta Reduces Complications from Neutropenia in Non-Hodgkin’s and Hodgkin’s Lymphomas (January 5, 2007)

According to results recently presented at the 2006 annual meeting of the American Society of Hematology, the use of Neulasta® (pegfilgrastim) during the first courses of chemotherapy significantly reduces... Continue Reading

Guidelines Address Prevention of Neutropenia (July 13, 2006)

According to updated recommendations from the American Society of Clinical Oncology, use of blood cell growth factors to prevent febrile neutropenia is warranted when risk of febrile neutropenia is 20%... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS